Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.39 |
| ▸ | CCND1 | P24385 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502509 | 0.79 | KCNA5 (0.52) | KCNA5KCNH2GAAMAPTALDH1A1 | |
| SCHEMBL12169929 | 0.78 | KCNH2 (0.51) | KCNA5KCNH2GAAMAPTALDH1A1 | |
| SCHEMBL19619170 | 0.77 | KCNA5 (0.42) | KCNA5KCNH2MEN1POLBKMT2A | |
| SCHEMBL8068675 | 0.76 | ELANE (0.48) | GAAMAPTALDH1A1RAB9AMEN1 | |
| SCHEMBL3119156 | 0.75 | GAA (0.57) | GAAMAPTALDH1A1RAB9ACCNE1 | |
| SCHEMBL29416441 | 0.75 | GAA (0.57) | GAAMAPTALDH1A1RAB9ACCNE1 | |
| SCHEMBL2369443 | 0.74 | ALDH1A1 (0.55) | GAAMAPTALDH1A1RAB9AKMT2A | |
| SCHEMBL8073672 | 0.73 | ELANE (0.51) | KCNA5KCNH2GAAALDH1A1RAB9A | |
| SCHEMBL25382124 | 0.72 | DCPS (0.52) | KCNA5KCNH2MAPTRAB9AMEN1 | |
| SCHEMBL31243210 | 0.72 | DCPS (0.52) | KCNA5KCNH2MAPTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| CN-102753535-A | Quinazolines as Potassium Channel Inhibitors | BRISTOL MYERS SQUIBB CO | 2012-10-24 | — | — | CN | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2473487-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KCNA5 48/4885KCNH2 9/4885ENPP1 4035/4885 |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KCNA5 48/4885KCNH2 9/4885ENPP1 4035/4885 |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KCNA5 48/4885KCNH2 9/4885ENPP1 4035/4885 |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNH3, KCNQ4 | KCNA5 46/4885KCNH2 7/4885ENPP1 4171/4885 |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | KCNA5 48/4885KCNH2 9/4885ENPP1 4035/4885 |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KCNA5 48/4885KCNH2 9/4885ENPP1 4035/4885 |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KCNA5 48/4885KCNH2 9/4885ENPP1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.